Sabuwar maganin gwaji don kula da tics daga Cutar Tourette

A cewar wani sabon bincike na farko, yara da matasa masu fama da ciwon Tourette waɗanda aka yi musu magani da maganin gwaji da ake kira ecopipam na iya samun sakamako mai kyau akan gwajin cutar tic bayan watanni uku. Binciken da aka fitar a yau, Maris 30, 2022, za a gabatar da shi a Cibiyar Nazarin Kwayoyin cuta ta Amurka ta 74th Annual Meeting da ake gudanar da mutum a Seattle, Afrilu 2 zuwa 7, 2022 kuma kusan, Afrilu 24 zuwa 26, 2022. Tourette ciwo ne rashin lafiyar jijiyoyin jiki da ke tattare da motsin motsi da tics na magana, waɗanda motsi ne masu maimaitawa da sautin murya wanda ya haifar da yunƙurin samar da su.

"Sakamakon mu yana da ban sha'awa, saboda suna ba da shawarar ecopipam yana nuna alƙawari a matsayin magani don rage adadin, mita da kuma tsanani na tics da matasa ke fama da ciwon Tourette," in ji marubucin binciken Donald L. Gilbert, MD, na Cibiyar Kiwon Lafiyar Yara ta Cincinnati. Cibiyar a Ohio, da Fellow of American Academy of Neurology. "Wannan gaskiya ne musamman saboda yawancin mutanen da ke fama da cutar da ke shan magungunan da ake samu a halin yanzu suna da alamun rauni ko kuma samun ƙarin nauyi ko wasu illolin."

Binciken ya duba yara 149 da matasa masu shekaru shida zuwa 17 masu fama da ciwon Tourette. An raba su zuwa ƙungiyoyi biyu: 74 an bi da su tare da ecopipam, 75 tare da placebo.

Masu bincike sun auna tsananin tics ɗin mahalarta ta amfani da ma'auni na tic guda biyu a farkon binciken da kuma bayan watanni uku. Gwaji na farko yana auna injina da tics na murya kuma yana da matsakaicin maki 50. Gwaji na biyu yana duban gabaɗayan alamun tic da tsananin lahani da ke da alaƙa da tic. Yana da matsakaicin ma'auni na 100. Mahimman ƙididdiga a kan ɗayan gwaje-gwajen suna nuna alamun cututtuka masu tsanani da mummunan tasiri a rayuwar yau da kullum.

Bayan watanni uku, masu bincike sun gano cewa rukunin da ke shan ecopipam yana da ƙarancin tics da ƙarancin ƙarfi kuma suna yin mafi kyau gabaɗaya bisa ga duka gwajin gwaji.

A matsakaita, mahalarta da ke shan ecopipam sun inganta injin su da ƙimar sautin tsananin sauti daga 35 zuwa 24, raguwar 30%. Wannan idan aka kwatanta da waɗanda ke ɗaukar placebos, waɗanda suka haɓaka daga matsakaicin ƙimar tic na 35 zuwa 28 a lokaci guda, raguwar 19%.

Lokacin da masu bincike suka kalli maki don gwaji na biyu don kimanta tasirin ecopipam gaba ɗaya, sun gano cewa waɗanda ke shan maganin sun inganta daga matsakaicin maki 68 zuwa 46, raguwar 32%, idan aka kwatanta da waɗanda ke ɗaukar placebo, wanda ya inganta daga matsakaicin maki na 66 zuwa 54, raguwar 20%.

Gilbert ya lura cewa 34% na mahalarta shan ecopipam sun sami sakamako masu illa kamar ciwon kai da gajiya, yayin da 21% na masu shan placebos suka yi.

"Bincike na baya ya nuna matsalolin da ke tattare da dopamine, mai kwakwalwa a cikin kwakwalwa, na iya danganta da alamun cututtuka na Tourette, kuma masu karɓa na D1 dopamine suna taka muhimmiyar rawa," in ji Gilbert. “ Ana samun masu karɓar dopamine a cikin tsarin juyayi na tsakiya. Lokacin da suke karɓar dopamine, suna ƙirƙirar sigina don ayyuka daban-daban na tunani da na jiki kamar motsi. Masu karɓa daban-daban suna taimakawa sarrafa ayyuka daban-daban. Yayin da ecopipam ke cikin lokacin gwaji, shine magani na farko da ya yi niyya ga mai karɓar D1 maimakon mai karɓar D2, wanda shine wanda magunguna ke niyya a halin yanzu a kasuwa. Sakamakonmu ya nuna cewa ecopipam ya cancanci ƙarin nazari a matsayin zaɓin magani mai dacewa don ciwon Tourette a cikin matasa a nan gaba. "

Iyakar binciken shine tsawon watanni uku. Gilbert ya lura cewa ko da yake yana da ma'auni na irin wannan binciken, zai zama mahimmanci don koyo idan ci gaban alamun ya daɗe.